Company intelligence / Profile preview
Advanced Life Sciences Holdings
- Ownership
- Private
- Employees
- ~25
- Development stage
- Commercial
Overview
Advanced Life Sciences Holdings was a biopharmaceutical company focused on developing novel antibiotics and therapeutics for infectious diseases, cancer, and inflammatory conditions. Its lead program was cethromycin ("Restanza"), an oral antibiotic targeting community-acquired bacterial pneumonia and select biodefense pathogens. The company also developed ALS-357 for malignant melanoma and ALS-886 for inflammation-related tissue damage such as ARDS. Operations were suspended due to lack of liquidity in 2011; the company's SEC registration was revoked in 2017.
- Therapeutic areas
- OncologyPulmonologyInfectious Diseases
- Modalities
- Small moleculeNatural product
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Advanced Life Sciences Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advanced Life Sciences Holdings.